

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18, 38/55 // (A61K 38/55, 38:18)	A1	(11) International Publication Number: WO 98/46254 (43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/EP98/02029 (22) International Filing Date: 8 April 1998 (08.04.98) (30) Priority Data: 08/833,959 11 April 1997 (11.04.97) US (71) Applicant (for all designated States except US): BOEHRINGER MANNHEIM GMBH [DE/DE]; Sandhofer Straße 116, D-68305 Mannheim (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): BARTKE, Ilse [DE/DE]; Eichenstraße 25a, D-82347 Bernried (DE). UNGER, Jürgen [DE/DE]; Sperberweg 5, D-84036 Landshut (DE). GENAIN, Claude [FR/US]; 568 Marin Avenue, Mill Valley, CA 94941 (US). HAUSER, Stephen [US/US]; P.O. Box 1588, Ross, CA 94957 (US). (74) Common Representative: BOEHRINGER MANNHEIM GMBH; Werk Penzberg, Patentabteilung (RE-TB), Post- fach 11 52, D-82372 Penzberg (DE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NGF FOR THE PREVENTION OF DEMYELINATION IN THE NERVOUS SYSTEM		
(57) Abstract The present invention concerns a process for preventing the demyelination of nerve fibers, in particular of human nerve fibers, in which the human being is treated with nerve growth factor (NGF) or active fragments of NGF. In addition, a composition for treating diseases in which a demyelination of nerve fibers occurs is disclosed. The composition contains NGF or an active fragment thereof as the active substance together with the usual pharmaceutical vehicles, auxiliary substances, fillers and diluents.		